BSEBoard Meeting5d ago · 14 Aug 2026, 04:29 pm
Pursuant to provisions of Regulation 30, 33 and 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company ....
Medico Intercontinental Ltd · 539938
✦ AI SummaryResults
Medico Intercontinental Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with a limited review report from its statutory auditors. The company has also announced the date and details of its Annual General Meeting (AGM) to be held on September 30, 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Medico Intercontinental Ltd - 539938 - Board Meeting Outcome for Compliances Of Regulation 30, 33 And 42 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
Attachments (1)
📄pdf
Download →
782caa03-03e8-4c86-b5de-b229443f07bf.pdf
View document text
= = INTERCONTINENTAL LTD.
CIN: L24100GJ1984PLC111413
Reg. Office: 1-5th Floor, Aditraj Arcade, Nr Karma Shreshtha Tower, 100 Ft Rd, Satellite, Ahmedabad - 380015.
Date: 14t August, 2026
Listing Compliances, Listing Compliances,
BSE Limited, CSE - India,
P.J. Towers, 7, Lyons Range, Dalhousie
Fort, Mumbai - 400001. Kolk- a70t00a01 .
Scrip Code: 539938; Scrip Id: MIL
Subject: Outcome of Board Meeting and Compliances of Regulation 30, 33 and 42 of SEBI (Listing
Obligation and Disclosure Requirements) Regulations, 2015.
Dear Sir/Ma’am,
Pursuant to provisions of Regulation 30, 33 and 42 of SEBI (Listing Obligations and Disclosure
Requirements) Regulation, 2015, this is to inform you that the Board of Directors of the Company at its
meeting held today i.e, August 14, 2026, inter alia, considered and approved:
1. Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended
on June 30, 2026 along with Limited review report issued by M/s. V Goswami & Co, Statutory
Auditors of the Company.
2. Notice of Annual General Meeting, Board’s report along with Annexures thereon.
3. The Annual General Meeting of the Company will be held on Wednesday, 30 September, 2026 at
02:00 P.M. through Video Conferencing (VC) / Other Audio Visual Means (OAVM).
4. The cut-off date for the purpose of the Annual General Meeting is 23+ September, 2026.
5. The Register of members and share transfer books will remain closed from 24t September, 2026
to 30t September, 2026 (both days inclusive) for the purpose of the AGM.
6. The e-voting will commence from Sunday, 27% September, 2026 at 9:00 AM. and shall conclude
on Tuesday, 29™ September, 2026 at 5:00 P.M.
7. Mr. Yash Mehta, Practicing Company Secretary has been appointed as Scrutinizer for the purpose
of e-voting at Annual General Meeting.
Further, please find enclosed “Standalone and Consolidated unaudited Financial Results along with
Limited Review Report” for the quarter ended on June 30, 2026 as Annexure 1 and same is also available
on the website of the Company viz. www.medicointercontinental.com
The Board Meeting of the Company commenced at 01:00 PM and concluded at 04:20 PM.
This is for your information and records.
Thanking You,
FORMEDICO INTERCONTI TAL LIMITED
CONTIA,
AuMEDABRD)
Samir D Shah
Managing Director
(DIN: 03350268)
Godown Address: 12 & 19/1a, Madhav Estate, Near IBP Petrol pump, Forest Section-1, Aslali, Ahmedabad-382427.
Ph. No.: 079-26742739, Fax No. 079-26742740. Email ID: mail@medicointercontinental.com
Website: www.medicointercontinental.com
RBI UCN NO. :- 897783
V. GO SWAMI 8 Co. C&AG REG NO. :- WR4659
WoiA CHARTERED ACCOUNTANTS | cMoSrM E . s:-i smGJm-r0v1a-o0r1e4r9i6e5s8
B-1006, Titanium Square, Opp.Thaltej Metro, S.G. Highway, Thaltej, Ahmeabad-380059.
M :+91 94287 33430, +91 97247 28711 | E-mail : thegoswami@gmail.com | www.goswami.in
Independent Auditor’s Review Report on Standalone Unaudited Quarterly Financial Results of the
Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 (as amended)
TO THE BOARD OF DIRECTORS OF MEDICO INTERCONTINENTAL LIMITED
We have reviewed the accompanying Statements of Standalone Unaudited Financial Results of
MEDICO INTERCONTINENTAL LIMITED (“the company”), for the quarter ended June 30, 2026 (“the
Statement”), being submitted by the Company pursuant to the requirement of Regulation 33 of
the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended,
including relevant circulars issued by the SEBI from time to time.
This Statement, which is the responsibility of the Company's Management and approved by the
Company's Board of Directors, has been prepared in accordance with the recognition and
measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial
Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with
relevant rules issued thereunder and other accounting principles generally accepted in India. Our
responsibility is to express a conclusion on the Statement based on our review.
We conducted our review of the Statement in accordance with the Standard on Review
Engagements (SRE) 2410 ‘Review of Interim Financial Information Performed by the Independent
Auditor of the Entity ', issued by the Institute of Chartered Accountants of India (ICAl). A review of
interim financial information consists of making inquiries, primarily of the Company's personnel
responsible for financial and accounting matters, and applying analytical and other review
procedures. A review is substantially less in scope than an audit conducted in accordance with
Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and
consequently does not enable us to obtain assurance that we would become aware of all significant
matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
RBI UCN NO. :- 897783
V. GO SWAMI 8 C O. C&AG REG NO. :- WR4659
™woi1A CHARTERED ACCOUNTANTS | cMoSrM E . s:-a nmGJi-r0v1s-o0r1s4t9i6z5s8
B-1006, Titanium Square, Opp.Thaltej Metro, S.G. Highway, Thaltej, Ahmeabad-380059.
M : +91 94287 33430, +91 97247 28711 | E-mail : thegoswami@gmail.com | www.goswami.in
Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention
that causes us to believe that the accompanying Statement, prepared in accordance with the
recognition and measurement principles laid down in the aforesaid Indian Accounting Standard
and other accounting principles generally accepted in India, has not disclosed the information
required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed,
or that it contains any material misstatement.
For, V. GOSWAMI & CO,
Chartered Accountants
(FRN:0128769W)
QQ/L/—/
vv@;
(Partner)
Mem No:119809
Place: -Ahmedabad
Date: - 14/08/2026
UDIN: 26119809YXXYDH9130
MEDICO INTERCONTINENTAL LIMITED
CIN: 1241006/1984PLC111413
Regd. Off: 1-5TH FLOOR, ADIT RAJ ARCADE NR KARMA, SHRESHTHA TOWER, 100 FT RD, SATELLITE,Ahmedabad GJ 380015 IN
Tel No. 079-26742739 E-mail:- mail@medicointercontinental.com Website: www.medicointercontinental.com
Statement of Standalone Unaudited Financial Results for the Quarter ended June 30, 2026
(Rs in Lakhs)
Quarter ended Year ended
STANDALONE STANDALONE
3Months ended | Preceding 3 Months | Corresponding3 | _ Previous year ended
ended months ended in
previous vear on
sr. Particulars 30-06-2026 31-03-2026 30-06-2025 31032026
NoJ| Unaudited Audited Unaudited Audited
Revenues
1 Revenue from Operations 1433.29 1582.34] 1346.68] 5446.08]
2 Other Income 50.73] 72.98 24.19) 234.54
3 [Total Revenue (A) 1524.02] 1655.31] 1370.86] 5680.62)
7 [Expenses
(2)_[Cost of materials consumed 0.000} 0.00 0.000 0.00]
(b) [Purchases of stockin-trade 1189.11 1306.79) 947.94] 4486.22|
(c) |Changes in inventories of finished goods and stock-in-trade 87.64] 3818 12851 82.69)
(d) [Employee benefits expense 5635 66.18 5088 246.03
() [Finance costs 47.83) 39.87 2352 166.83)
(7)_|Depreciation and amortisation expense 11.25) 15.83 17.56 69.35)
(¢)_|Other expenses 5055 11538 108.76 317.86
Total Expenses (B) 1442.73] 1582.23] 1297.18] 5368.98)
5 [Profit/{Loss) before exceptional items & tax (1-4) 81.29] 73.08) 73.68 311.64)
6 |Exceptional items 0.00 0.00 0.00 0.00)
7_|Profit/{Loss) for the period from operations before tax (5+6) 81.29) 73.08 73.68| 311.64]
8 [Tax expense 20.53] 30.67 18.08] 93.28)
() [Current Tax 2197 31.22 1971 95.07|
(b) _|Deffered Tax 144 -0.55. 163 -1.79)
9 |Profit/(Loss) for the period from continuing operations (7-8) 60.76] 42.41] 55.60) 218.359)
10 [Profit/{loss) for the period from discontinued operations 000 0.00| 0.00 0.00)
11 [Tax expense of discontinued operations 000 0.00) 000 0.00)
12 [Profit/{loss) for the period from Discontinued operations (after tax] 000 0.00
[Showing first 8,000 characters — download PDF for full document]